Published on Thu Aug 19 2021

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).

A Pérez-Martínez, M Mora-Rillo, C Ferreras, P Guerra-García, B Pascual-Miguel, C Mestre-Durán, A M Borobia, A J Carcas, J Queiruga-Parada, I García, E Sánchez-Zapardiel, M Gasior, R De Paz, A Marcos, J L Vicario, A Balas, M A Moreno, C Eguizabal, C Solano, J R Arribas, R de Miguel Buckley, R Montejano, B Soria

SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy.

1
1
14
Abstract

Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy.